Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients
Table 2
Changes in biochemical markers at 8 and 16 weeks of treatment.
Variable
Baseline
8 weeks
16 weeks
Glucose (mg/dL)
113.0 (93.0; 172.0)
107.0 (90.0; 154.0)
0.103
112.0 (95.0; 152.0)
0.383
Urea (mg/dL)
32.0 (27.4; 38.0)
31.0 (25.0; 40.0)
0.884
31.6 (26.0; 37.0)
0.781
Creatinine (mg/dL)
0.85 (0.68; 1.01)
0.8 (0.66; 0.94)
0.029
0.80 (0.68; 0.94)
0.030
Uric Acid(mg/dL)
5.8 ± 1.4
5.6 ± 1.4
0.002
5.4 ± 1.5
0.002
Total cholesterol (mg/dL)
199.1 ± 60.1
132.5 ± 48.3
0.001
134.4 ± 47.2
0.001
HDL cholesterol (mg/dL)
38.9 (33.0; 47.0)
39.8 (33.2; 49.5)
0.968
38.7 (33.4; 46.29)
0.400
Non-HDL cholesterol (mg/dL)
154.2 ± 59.2
90.7 ± 48.5
0.001
94.2 ± 45.4
0.001
Triglycerides (mg/dL)
219 (126.0; 336.0)
154.0 (107.0; 218.5)
0.001
156.0 (108.0; 231.0)
0.001
LDL cholesterol (mg/dL)
119.0 (75.4; 143.6)
46.6 (38.4; 74.8)
0.001
51.7 (38.5; 79.0)
0.001
VLDL cholesterol (mg/dL)
34.0 (22.0; 52.0)
27.0 (19.5; 33.0)
0.001
24.0 (19.0; 33.0)
0.001
Atherogenic Index
0.75 (0.43; 0.94)
0.59 (0.39; 0.78)
0.001
0.62 (0.42; 0.75)
0.002
baseline vs 8 weeks; + baseline vs 16 weeks; 8 weeks vs 16 weeks. The nonparametric Wilcoxon rank sum test for nonnormal variables and the paired T-student test for data with normal distribution. The variable with the smallest number of subjects was VLDL-C with 81 patients for the 16th week.
